Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top 10 Drugs: Weighing Pharma's Golden Eggs

Executive Summary

INFOGRAPHIC: A relatively small number of relatively costly drugs account for a sizable proportion of pharma industry revenues. But what are its biggest golden eggs, how reliant are companies on those products, and how has the situation evolved over time?

You may also be interested in...



10 Triumphant Drug Launches Of The Decade

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

Morepen Adds ‘Blockbusters’ To API Portfolio

India’s Morepen Laboratories has added two “blockbuster drugs” and one niche product to its API portfolio for sale in its domestic and global markets as it looks to move up the value chain following approval for its in-house R&D center.

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

INFOGRAPHIC: maturing cancer and autoimmune biologics still top the league for global revenues, but biosimilars are snapping at their heels.

 

Related Content

Topics

UsernamePublicRestriction

Register

SC125663

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel